- $42.21m
- $30.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.09 | ||
| Price to Tang. Book | 14.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -202.8% | ||
| Return on Equity | -175.11% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.49 | 2.88 | 28.31 | 2.3 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
Directors
- Itzhak Goldberg CHM (72)
- Jay Venkatesan PRE (49)
- Gregory Curhan CFO (59)
- Jennifer Rhodes SVP (50)
- John Neylan SVP (66)
- Victor Ganzi IND (74)
- Allen Nissenson IND (74)
- Gilbert Omenn IND (79)
- Karen Wilson IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 6th, 1998
- Public Since
- February 5th, 2021
- No. of Shareholders
- 245
- No. of Employees
- 32
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 10,270,285
- Address
- 451 D Street, 5Th Floor, BOSTON, 02459
- Web
- https://elicio.com/
- Phone
- +1 8572090050
- Contact
- Heather Divecchia
- Auditors
- Moss Adams LLP Seattle, Washington
Upcoming Events for ELTX
Q3 2024 Elicio Therapeutics Inc Earnings Release
Similar to ELTX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Elicio Therapeutics share price?
As of Today at 20:28 UTC, shares in Elicio Therapeutics are trading at $6.68. This share price information is delayed by 15 minutes.
How has the Elicio Therapeutics share price performed this year?
Shares in Elicio Therapeutics last closed at $6.68 and the price had moved by -37.39% over the past 365 days. In terms of relative price strength the Elicio Therapeutics share price has underperformed the S&P500 Index by -50.18% over the past year.
What are the analyst and broker recommendations for Elicio Therapeutics?
The overall consensus recommendation for Elicio Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Elicio Therapeutics dividend yield?
Elicio Therapeutics does not currently pay a dividend.
Does Elicio Therapeutics pay a dividend?
Elicio Therapeutics does not currently pay a dividend.
When does Elicio Therapeutics next pay dividends?
Elicio Therapeutics does not currently pay a dividend.
How do I buy Elicio Therapeutics shares?
To buy shares in Elicio Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Elicio Therapeutics?
As of the previous close price of $6.68, shares in Elicio Therapeutics had a market capitalisation of $68.61m.
Where are Elicio Therapeutics shares listed?
Here are the trading details for Elicio Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ELTX
What kind of share is Elicio Therapeutics?
Based on an overall assessment of its quality, value and momentum Elicio Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Elicio Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Elicio Therapeutics is $10.00. That is 49.7% above the last closing price of $6.68.
Analysts covering Elicio Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.68 for the next financial year.
What is the trend in the Elicio Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elicio Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -9.51%.
As of the last closing price of $6.68, shares in Elicio Therapeutics were trading -2.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Elicio Therapeutics PE Ratio?
The Elicio Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Elicio Therapeutics?
Elicio Therapeutics' management team is headed by:
- Itzhak Goldberg - CHM
- Jay Venkatesan - PRE
- Gregory Curhan - CFO
- Jennifer Rhodes - SVP
- John Neylan - SVP
- Victor Ganzi - IND
- Allen Nissenson - IND
- Gilbert Omenn - IND
- Karen Wilson - IND